E-mail us:
service@prospectnews.com
Or call: 212 374 2800
Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
Add to balance / Manage account
Not logged in
Prospect News home
>
Main news index
>
All issuers starting with A
>
Issuers starting with A, CV only
>
All stories on Axcan Pharma Inc.
>
Stories on Axcan Pharma Inc., CV only
Search again
Enter part or all of the issuer name:
Market:
All markets
No structured products
Bank loans
Canadian bonds
CLOs
Convertibles
Distressed debt
Emerging markets
High yield
Investment grade
Liability management
Municipals
PIPEs
Preferreds
Private placements
All leveraged markets
Structured products
Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each.
All others are $1.00 each. Headlines in
gray
are not currently covered by your subscription.
Axcan Pharma Inc.
1/25/2008
BKCVHY
Moody's rates Axcan loans Ba2, notes B3
6/29/2007
CV
Axcan investors convert all $125 million of 4.25% notes ahead of redemption
5/15/2007
CV
Axcan Pharma calls 4.25% convertibles
5/10/2007
CV
Axcan to redeem 4.25% convertibles
9/10/2004
CV
Merrill: Regal-Beloit, Axcan, Global Imaging convertibles would suffer biggest price correction in takeover event
3/5/2003
CV
Axcan says greenshoe exercised, raising convertibles to $125 million
3/4/2003
CV
Market Commentary:
Inco deals steady out of gate; Watson trading up in gray as credit, put offset pricey terms
2/28/2003
CV
Market Commentary:
LNR, Chesapeake, Axcan rise; buyers for Gap's convertibles as stock slides on sales news
2/28/2003
CV
New Issue: Axcan upsized $110 million convertibles yield 4.25%, up 38%
2/27/2003
CV
Market Commentary:
New issues dominate market as funding window narrows
2/26/2003
CV
Market Commentary:
New issues bid up in gray; Tyco's new converts gain sharply, power names dive
2/25/2003
CV
Axcan Pharma $100 million convertible talked to yield 4.25-4.75%, up 25-30%
2/25/2003
CV
Market Commentary:
Credit markets, new deals stir players out of shadows
2/24/2003
CV
Market Commentary:
Very slow trading day, with players hanging in shadows
2/24/2003
CV
Axcan Pharma plans $100 million convertible
©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.
